- Home
- RNP vs FTRE Comparison
RNP vs FTRE Comparison
Compare RNP & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNP
- FTRE
- Stock Information
- Founded
- RNP 2003
- FTRE 1996
- Country
- RNP United States
- FTRE United States
- Employees
- RNP N/A
- FTRE N/A
- Industry
- RNP Investment Managers
- FTRE Medical Specialities
- Sector
- RNP Finance
- FTRE Health Care
- Exchange
- RNP Nasdaq
- FTRE Nasdaq
- Market Cap
- RNP 1.0B
- FTRE 864.4M
- IPO Year
- RNP N/A
- FTRE N/A
- Fundamental
- Price
- RNP $21.24
- FTRE $10.24
- Analyst Decision
- RNP
- FTRE Hold
- Analyst Count
- RNP 0
- FTRE 9
- Target Price
- RNP N/A
- FTRE $13.06
- AVG Volume (30 Days)
- RNP 117.6K
- FTRE 1.0M
- Earning Date
- RNP 01-01-0001
- FTRE 11-05-2025
- Dividend Yield
- RNP 7.94%
- FTRE N/A
- EPS Growth
- RNP N/A
- FTRE N/A
- EPS
- RNP N/A
- FTRE N/A
- Revenue
- RNP N/A
- FTRE $2,733,500,000.00
- Revenue This Year
- RNP N/A
- FTRE N/A
- Revenue Next Year
- RNP N/A
- FTRE N/A
- P/E Ratio
- RNP N/A
- FTRE N/A
- Revenue Growth
- RNP N/A
- FTRE N/A
- 52 Week Low
- RNP $15.52
- FTRE $3.97
- 52 Week High
- RNP $21.27
- FTRE $25.28
- Technical
- Relative Strength Index (RSI)
- RNP 36.12
- FTRE 52.83
- Support Level
- RNP $21.14
- FTRE $10.25
- Resistance Level
- RNP $21.88
- FTRE $10.91
- Average True Range (ATR)
- RNP 0.27
- FTRE 0.57
- MACD
- RNP -0.02
- FTRE -0.01
- Stochastic Oscillator
- RNP 13.51
- FTRE 46.96
About RNP Cohen & Steers REIT and Preferred and Income Fund Inc.
Cohen & Steers REIT and Preferred Income Fund Inc is a diversified, closed-ended investment management fund. Its investment objective is to provide high current income with capital appreciation as its secondary objective. The Fund invests at least its total assets in common stocks issued by real estate investment trusts (REITs) and preferred securities under normal circumstances.
About FTRE Fortrea Holdings Inc.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.